Back To Top

You have matched to 8 trials

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

<span class="highlight">Immunotherapy</span> and <span class="highlight">Radiation</span> for Advanced CEA Positive Breast Cancer

A Phase I Study of M5A-IL2 Immunocytokine Combined With Stereotactic Body <span class="highlight">Radiation</span> Therapy (SBRT) in Patients With Metastatic Colorectal Cancer or CEA-Positive Metastatic Breast Cancer

Purpose: To study the safety, best dose, effects (good and bad), and anti-cancer activity of M5A-IL2, an experimental <span class="highlight">immunotherapy,</span> with standard of care stereotactic body <span class="highlight">radiation</span> therapy (SBRT).

Who is this for?: People with advanced (some stage III) or metastatic (stage IV) CEA+ breast cancer who have no standard treatment options available. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic body <span class="highlight">radiation</span> therapy (SBRT), 3 sessions within 1 week</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">M5A-IL2 (M5A-ICK), by injection, 3 times within 3 days</li> <li class="seamTextUnorderedListItem">PET/CT scans</li> <li class="seamTextUnorderedListItem">MRI scans and/or bone scans</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Carcinoembryonic Antigen (CEA) is a protein that is present in some cancers, including breast cancer.</li> <li class="seamTextUnorderedListItem">M5A-IL2 (M5A-ICK) is an experimental <span class="highlight">immunotherapy</span> called an immunocytokine.</li> <li class="seamTextUnorderedListItem">Immunocytokines are small proteins that regulate the activity of immune cells that are important for anti-cancer activity.</li> <li class="seamTextUnorderedListItem">The M5A-IL2 immunocytokine (M5A-ICK) combines the cancer targeting features of the M5A antibody with the immune system regulation properties of the cytokine IL-2.</li> <li class="seamTextUnorderedListItem">Stereotactic body <span class="highlight">radiation</span> therapy (SBRT) uses special equipment to position a patient and deliver <span class="highlight">radiation</span> to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06130826' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancer.org/cancer/managing-cancer/treatment-types/immunotherapy/cytokines.html' target='_blank'>American Cancer Society: Cytokines</a> </li></ul>
1

<span class="highlight">Immunotherapy</span> and <span class="highlight">Radiation</span> for Advanced CEA Positive Breast Cancer

A Phase I Study of M5A-IL2 Immunocytokine Combined With Stereotactic Body <span class="highlight">Radiation</span> Therapy (SBRT) in Patients With Metastatic Colorectal Cancer or CEA-Positive Metastatic Breast Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Icon

Visits:
At least 6 visits within 2 weeks

Icon

ClinicalTrials.gov: NCT06130826

Icon

Phase I

2

Cemiplimab <span class="highlight">Immunotherapy</span> and Blockade of Tumor Blood Vessels for Metastatic Breast Cancer That Has Spread to the Liver

Pilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Breast Cancer

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of cemiplimab (Libtayo®) <span class="highlight">immunotherapy</span> and a new type of procedure called transarterial radioembolization (TARE) with Y90 SIR-S Spheres.

Who is this for?: People with stage IV (metastatic) breast cancer that has spread to the liver and who have received at least one line of chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cemiplimab (Libtayo®), by IV, every 3 weeks for 1 year</li> <li class="seamTextUnorderedListItem">Y90 SIR-Spheres, by injection into the tumor, 2 times within 2 months</li> <li class="seamTextUnorderedListItem">Biopsy, 2 times within 1.5 months</li> <li class="seamTextUnorderedListItem">Blood tests</li> <li class="seamTextUnorderedListItem">CT scan or MRI scan</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Cemiplimab (Libtayo®) is a type of <span class="highlight">immunotherapy</span> called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Transarterial radioembolization (TARE) is a treatment that uses radioactive microspheres, such as Y90 SIR-S Spheres, to block liver tumor arteries and deliver radiotherapy to kill or slow tumor growth.</li> <li class="seamTextUnorderedListItem">Y90 SIR-S Spheres are a medical device used in selective internal <span class="highlight">radiation</span> therapy (SIRT). They work from the inside, targeting <span class="highlight">radiation</span> to the tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06860815' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.libtayo.com/cscc/what-is-libtayo?gclsrc=aw.ds&gad_source=1&gad_campaignid=21818392314&gclid=CjwKCAjw-svEBhB6EiwAEzSdrqVrcE526ont6BY7LSTfDrcWHrRlNbq3aKo67h3-MT7X9HJ1CwupdBoCOCwQAvD_BwE' target='_blank'>Regeneron: Cemiplimab</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.sirtex.com/us/patients/sir-spheres-y-90-resin-microspheres/about-sir-spheres/' target='_blank'>Sirtex: Y90 SIR-Spheres</a> </li></ul>
2

Cemiplimab <span class="highlight">Immunotherapy</span> and Blockade of Tumor Blood Vessels for Metastatic Breast Cancer That Has Spread to the Liver

Pilot Study of Cemiplimab and Hepatic Radioembolization in Patients With Liver Dominant Metastatic Breast Cancer
Icon

Nearest Location from 94107:
353 miles
City of Hope Medical Center
Duarte, CA

Icon

Visits:
Every 3 weeks for 1 year

Icon

ClinicalTrials.gov: NCT06860815

Icon

Phase II

3

Palliative <span class="highlight">Radiation</span> and <span class="highlight">Immunotherapy</span> for People with Metastatic Breast Cancer

A Phase 2 Study of Palliative <span class="highlight">Radiation</span> in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of stereotactic <span class="highlight">radiation</span> with pembrolizumab (Keytruda®) <span class="highlight">immunotherapy.</span>

Who is this for?: Women with stage IV (metastatic) breast cancer who have received at least 2 lines of therapy, including 1 line of chemotherapy. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic radiation, 1-5 sessions</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Stereotactic <span class="highlight">radiation</span> (stereotactic radiosurgery) delivers high-dose, precisely-targeted <span class="highlight">radiation</span> in fewer doses than traditional <span class="highlight">radiation</span> therapy.</li> <li class="seamTextUnorderedListItem">Palliative <span class="highlight">radiation</span> reduces side effects of metastatic breast cancer.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of <span class="highlight">immunotherapy</span> called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04990921' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.oncolink.org/support/hospice-and-palliative-care/palliative-radiation-treatment#:~:text=Palliative%20radiation%20is%20the%20use,doses)%20than%20traditional%20radiation%20treatment.' target='_blank'>OncoLink: Palliative Radiation</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/keytruda' target='_blank'>Breastcancer.org: Pembrolizumab (Keytruda®)</a> </li></ul>
3

Palliative <span class="highlight">Radiation</span> and <span class="highlight">Immunotherapy</span> for People with Metastatic Breast Cancer

A Phase 2 Study of Palliative <span class="highlight">Radiation</span> in Combination With Pembrolizumab in Subjects With Unresectable Metastatic Stage IV Breast Cancer: Twisted Pink
Icon

Nearest Location from 94107:
1984 miles
James Graham Brown Cancer Center
Louisville, KY

Icon

Visits:
1 visit every 3 weeks

Icon

ClinicalTrials.gov: NCT04990921

Icon

Phase II

4

<span class="highlight">Radiation</span> with Pembrolizumab and Chemotherapy for PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Phase II Study of High Dose Radiotherapy in Combination With Pembrolizumab Plus Chemotherapy in Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer

Purpose: To study the safety, effects (good and bad), side effects and anti-cancer activity of <span class="highlight">radiation</span> combined with an <span class="highlight">immunotherapy,</span> pembrolizumab (Keytruda®) and chemotherapy.

Who is this for?: People with metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer that is PD‑L1 positive who have not yet received chemotherapy for metastatic disease. The cancer must have spread to at least two places in your body, with at least one site that can be treated with radiation. View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. </li> <li class="seamTextUnorderedListItem">Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread.</li> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of <span class="highlight">immunotherapy</span> called a PD-1 inhibitor, which is a type of immune checkpoint inhibitor. Blocking PD-1 may allow the body's immune system to detect and fight cancer cells.</li> <li class="seamTextUnorderedListItem">Researchers are studying whether giving targeted <span class="highlight">radiation</span> just before and during the first cycle of <span class="highlight">immunotherapy</span> and chemotherapy can help control metastatic triple negative breast cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06492759' target='_blank'>ClinicalTrials.gov</a> </li></ul>
4

<span class="highlight">Radiation</span> with Pembrolizumab and Chemotherapy for PD-L1 Positive Metastatic Triple Negative Breast Cancer

A Phase II Study of High Dose Radiotherapy in Combination With Pembrolizumab Plus Chemotherapy in Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Icon

Nearest Location from 94107:
2139 miles
Emory University Hospital/Winship Cancer Institute
Atlanta, GA

Icon

Visits:
Up to 2-4 vistis per month, follow up visits every 3 months

Icon

ClinicalTrials.gov: NCT06492759

Icon

Phase II

5

Dendritic Cell Vaccine <span class="highlight">Immunotherapy</span> for Metastatic Breast Cancer With Leptomeningeal Disease

Phase 2 Trial With a Safety Run-in of Combinatorial Therapies With Intrathecal (IT) Dendritic Cell Vaccines (cDC1s) inHER+ (Combined With IT Trastuzumab) and HER2- (Combined With IT Nivolumab) Breast Cancer (BC) Leptomeningeal Disease (LMD)

Purpose: To study the effects (good and bad), and anti-cancer activity of a dendritic cell vaccine combined with either trastuzumab (Herceptin®) or nivolumab (Opdivo®), depending on HER2 status.

Who is this for?: People with with metastatic (stage IV) HER2 positive or HER2 negative (hormone receptor-positive or triple negative) breast cancer that has spread into the fluid surrounding the brain and spinal cord, a condition called leptomeningeal disease (LMD). You must have received have received <span class="highlight">radiation</span> to the whole brain. You have (or can have) an Ommaya reservoir (a small device placed under the scalp that allows treatment to reach the fluid around your brain and spinal cord). You must be able to receive care at Moffitt Cancer Center in Tampa, Florida, as this trial is only offered at this location. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following based on whether your cancer is HER2-positive or HER2-negative: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1 (HER2-negative)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dendritic cell vaccine (cDC1), given directly into the fluid around the brain and spinal cord through your Ommaya reservoir</li> <li class="seamTextUnorderedListItem">Nivolumab (Opdivo®), 50 mg, given the same way, every 2 weeks</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2 (HER2-positive)</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Dendritic cell vaccine (cDC1), given directly into the fluid around the brain and spinal cord through your Ommaya reservoir</li> <li class="seamTextUnorderedListItem">Trastuzumab (Herceptin®), 150 mg, given the same way, weekly</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">In this trial, instead of IV or pill form, treatment is delivered directly into the fluid around the brain and spinal cord through an Ommaya reservoir. </li> <li class="seamTextUnorderedListItem">An Ommaya reservoir is a small device placed under the scalp that allows treatment to reach the fluid around your brain and spinal cord.</li> <li class="seamTextUnorderedListItem">Researchers are testing a dendritic cell vaccine, an <span class="highlight">immunotherapy</span> designed to teach the immune system to recognize and attack breast cancer cells. </li> <li class="seamTextUnorderedListItem">Trastuzumab is a targeted therapy that blocks the HER2 protein on cancer cells for HER2-positive disease.</li> <li class="seamTextUnorderedListItem"> Nivolumab is an <span class="highlight">immunotherapy</span> that helps immune cells attack cancer for HER2-negative disease.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07694986' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.moffitt.org/for-healthcare-professionals/clinical-perspectives/clinical-perspectives-story-archive/now-enrolling--novel-dendritic-cell-vaccines-immunotherapy-trial-for-her2-breast-cancer/' target='_blank'>Moffitt Cancer Center: Novel Dendritic Cell Vaccines Immunotherapy Trial For HER2+ Breast Cancer</a> </li></ul>
5

Dendritic Cell Vaccine <span class="highlight">Immunotherapy</span> for Metastatic Breast Cancer With Leptomeningeal Disease

Phase 2 Trial With a Safety Run-in of Combinatorial Therapies With Intrathecal (IT) Dendritic Cell Vaccines (cDC1s) inHER+ (Combined With IT Trastuzumab) and HER2- (Combined With IT Nivolumab) Breast Cancer (BC) Leptomeningeal Disease (LMD)
Icon

Nearest Location from 94107:
2395 miles
Moffitt Cancer Center
Tampa, FL

Icon

Visits:
Every 1-2 weeks

Icon

ClinicalTrials.gov: NCT07694986

Icon

Phase II

6

<span class="highlight">Radiation</span> Therapy, <span class="highlight">Immunotherapy,</span> and a PARP Inhibitor for Women with Advanced Triple Negative Breast Cancer

A Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Combinations of DNA-Damage Response Inhibitors and <span class="highlight">Immunotherapy</span> for the Augmentation of Immune Responses

Purpose: To study the safety and anti-cancer activity of using <span class="highlight">radiation</span> therapy and the <span class="highlight">immunotherapy</span> pembrolizumab (Keytruda®) with or without the PARP inhibitor olaparib (Lynparza®).

Who is this for?: Women with advanced (some stage III) or metastatic (stage IV) triple negative (ER-, PR-, HER2-) breast cancer who have not already received a PARP inhibitor or more than two systemic therapies for advanced disease. To enroll, you must not have a BRCA 1/2 mutation (inherited or tumor). View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be randomly assigned to 1 of 2 groups: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, 3 times</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®), by mouth, twice a day, for 6 weeks</li> <li class="seamTextUnorderedListItem"><span class="highlight">Radiation</span> therapy, daily, for five days</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, every 3 weeks, 3 times</li> <li class="seamTextUnorderedListItem"><span class="highlight">Radiation</span> therapy, daily, for five days</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®) is a type of <span class="highlight">immunotherapy</span> called a checkpoint inhibitor or PD-1 inhibitor. It helps the immune system to go after cancer cells by blocking the PD-1 protein.</li> <li class="seamTextUnorderedListItem">Pembrolizumab is approved to treat some advanced triple-negative breast cancer, but its use in this trial, however, is considered experimental.</li> <li class="seamTextUnorderedListItem">Olaparib (Lynparza®) is a PARP inhibitor. It works by blocking the action of poly (ADP-ribose) polymerase, an enzyme that helps repair DNA.</li> <li class="seamTextUnorderedListItem">Olaparib is approved to treat HER2-negative metastatic breast cancer in women with an inherited BRCA1/2 mutation. Its use in this trial, however, is considered experimental. </li> <li class="seamTextUnorderedListItem">Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT04683679' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://metastatictrialtalk.org/research-news/tnbc-treatment-update-2021/' target='_blank'>Metastatic Trial Talk: 2021 Update on Metastatic Triple-Negative Breast Cancer Treatment</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.mdanderson.org/cancerwise/does-immunotherapy-treat-breast-cancer.h00-159385101.html' target='_blank'>MD Anderson Cancer Center: Does Immunotherapy Treat Breast Cancer?</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/research-news/fda-approves-keytruda-for-pd-l1-pos-tnbc' target='_blank'>Breastcancer.org: FDA Approves Immunotherapy Keytruda for PD-L1-Positive Triple-Negative Breast Cancer</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.cancerresearchuk.org/about-cancer/cancer-in-general/treatment/targeted-cancer-drugs/types/PARP-inhibitors' target='_blank'>Cancer Research UK: PARP Inhibitors</a> </li></ul>
6

<span class="highlight">Radiation</span> Therapy, <span class="highlight">Immunotherapy,</span> and a PARP Inhibitor for Women with Advanced Triple Negative Breast Cancer

A Phase II Study of Pembrolizumab and Ablative Radiotherapy With or Without Olaparib in Metastatic Triple-Negative Breast Cancers : Initial Test Cohorts of a Platform Trial to Sequentially Investigate Combinations of DNA-Damage Response Inhibitors and <span class="highlight">Immunotherapy</span> for the Augmentation of Immune Responses
Icon

Nearest Location from 94107:
2539 miles
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, NJ

Icon

Visits:
8 visits over 2 months

Icon

ClinicalTrials.gov: NCT04683679

Icon

Phase II

7

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients

Purpose: To study the safety and effects (good and bad) of using pembrolizumab (Keytruda®) along with stereotactic radiosurgery (SRS) to treat breast cancer that has spread to the brain.

Who is this for?: Women with metastatic (stage IV) breast cancer and at least two brain metastases. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Pembrolizumab (Keytruda®), by IV, once every 3 weeks, ongoing</li> <li class="seamTextUnorderedListItem">Stereotactic Radiosurgery (SRS), once after the first treatment of pembrolizumab</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Keytruda is a type of <span class="highlight">immunotherapy</span> called a PD-1 inhibitor.</li> <li class="seamTextUnorderedListItem">It stimulates the body's immune system to go after cancer cells. </li> <li class="seamTextUnorderedListItem">It has been approved to treat certain types of cancer, but its use in breast cancer is considered experimental. </li> <li class="seamTextUnorderedListItem">Stereotactic radiosurgery is not surgery. It is a type of <span class="highlight">radiation</span> therapy that precisely targets metastases in the brain.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT03449238' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='http://mbcn.org/brain-mets/' target='_blank'>Metastatic Breast Cancer Network: Brain Metastases</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/symptoms/types/recur_metast/treat_metast/options/local/brain/radiosurgery' target='_blank'>Breastcancer.org: Stereotactic Radiosurgery for Brain Metastasis</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.keytruda.com' target='_blank'>Merck Oncology Information Page: Keytruda</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/treatment/immunotherapy/what' target='_blank'>Breastcancer.org: What is Immunotherapy?</a> </li></ul>
7

Pembrolizumab (Immunotherapy) And Radiosurgery (Radiation) to Treat Brain Metastases

Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
Icon

Nearest Location from 94107:
2567 miles
Weill Cornell Medicine
New York, NY

Icon

Visits:
1 visit every 3 weeks, ongoing

Icon

ClinicalTrials.gov: NCT03449238

Icon

Phase I-II

8

<span class="highlight">Radiation</span> for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast <span class="highlight">Radiation</span> Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery

Purpose: To study the safety, effects (good and bad), and anti-cancer activity of adding <span class="highlight">radiation</span> to routine medications for breast cancer.

Who is this for?: People with stage I, stage II, stage III, or stage IV (metastatic) breast cancer who cannot or do not want to receive surgery. You must not be receiving systemic therapy (except for hormone therapy, HER2-targeted therapy, or <span class="highlight">immunotherapy).</span> View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will be assigned to 1 of 2 groups, depending on node status: </p> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 1: Lymph Nodes Negative for Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li> </ul> <p class="seamTextPara"> <i class="seamTextEmphasis">Group 2: Lymph Nodes Positive for Cancer</i> </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Whole-breast and lymph node radiation, 5 times</li> <li class="seamTextUnorderedListItem">CT or MRI scan</li> <li class="seamTextUnorderedListItem">Questionnaires</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">Patients who cannot receive surgery for breast cancer have limited effective treatment options. <span class="highlight">Radiation</span> may provide long-lasting control of the tumor in patients who cannot or do not wish to receive surgery.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07122713' target='_blank'>ClinicalTrials.gov</a> </li></ul>
8

<span class="highlight">Radiation</span> for People who Cannot Receive Surgery for Stage I-IV Breast Cancer

Multi-institutional Prospective Pilot Study of Definitive Breast <span class="highlight">Radiation</span> Therapy for Invasive Breast Cancer Patients Not Undergoing Definitive Surgery
Icon

Nearest Location from 94107:
2604 miles
Stony Brook University Cancer Center
Stony Brook, NY

Icon

Visits:
5 visits, then follow-up for up to 5 years

Icon

ClinicalTrials.gov: NCT07122713

Icon

Phase NA

HELP GUIDE